Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development.
ATP-dependent RNA helicase A (DHX9) inhibitors have been reported in an Accent Therapeutics Inc. patent as potentially useful for the treatment of cancer.
Accent Therapeutics Inc. will receive $55 million up front and as much as $1.1 billion in milestones as part of a substantial new three-molecule deal with Astrazeneca plc, which committed to exploring what Astrazeneca’s oncology chief, José Baselga, called the "compelling" field of targeting RNA-modifying proteins (RMPs) for the treatment of cancer.